CC’s transdisciplinary development team has created a way to democratise gene editing. This IP-free gene editing method avoids the timescales and costs involved with commercially licensing current CRISPR/Cas9 editing techniques.
Author profile

マシュー ジョーンズ
バイオイノベーション部、上席サイエンティスト
Matthew Jones is a Senior Consultant at Cambridge Consultants delivering projects for clients working at the interface between biotechnology and engineering.
Matthew is also supporting the development of our internal capabilities in cell free biology, laboratory automation and design of experiment approaches.